NASDAQ:TECH Bio-Techne (TECH) Stock Price, News & Analysis $72.78 +0.12 (+0.17%) Closing price 11/6/2026 04:00 PM EasternExtended Trading$72.79 +0.01 (+0.01%) As of 11/6/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Bio-Techne Stock (NASDAQ:TECH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bio-Techne alerts:Sign Up Key Stats Today's Range$72.63▼$72.8050-Day Range$72.08▼$72.7852-Week Range$43.19▼$72.83Volume2.31 million shsAverage Volume2.83 million shsMarket Capitalization$11.43 billionP/E Ratio63.29Dividend Yield0.44%Price Target$68.92Consensus RatingHold Company Overview Bio-Techne is a life sciences company that develops and supplies products and services used in biological research, drug development, and clinical diagnostics. Its offerings include proteins, antibodies, immunoassays, and small molecules, as well as instruments and analytical tools for studying cells and biological processes. The company also provides technologies for protein analysis, molecular diagnostics, and spatial biology. Its portfolio includes products and services associated with brands such as R&D Systems, Tocris, ProteinSimple, and Advanced Cell Diagnostics. Founded in 1976, Bio-Techne serves pharmaceutical and biotechnology companies, academic and government research institutions, and clinical laboratories worldwide.AI Generated. May Contain Errors. Read More Bio-Techne Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreTECH MarketRank™: 2.20788043478 of 5 starsBio-Techne scored higher than 44% of companies evaluated by MarketBeat, and ranked 601st out of 886 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingHold Consensus RatingBio-Techne has received a consensus rating of Hold. The company's average rating score is 2.12, and is based on 1 strong buy rating, 1 buy rating, 14 hold ratings, and 1 sell rating.Downside RiskBio-Techne has a consensus price target of $68.92, representing about 5.3% downside from its current price of $72.78.Amount of Analyst CoverageBio-Techne has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Bio-Techne's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth12.57% Earnings GrowthEarnings for Bio-Techne are expected to grow by 12.57% in the coming year, from $1.75 to $1.97 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bio-Techne is 42.31, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.03.Price to Earnings Ratio vs. SectorThe P/E ratio of Bio-Techne is 42.31, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.60.Price to Earnings Growth RatioBio-Techne has a PEG Ratio of 5.28. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBio-Techne has a P/B Ratio of 5.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.88% of the float of Bio-Techne has been sold short.Short Interest Ratio / Days to CoverBio-Techne has a short interest ratio ("days to cover") of 2.88, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bio-Techne has recently increased by 2.26%, indicating that investor sentiment is decreasing. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldBio-Techne has a dividend yield of 0.44%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthBio-Techne does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Bio-Techne is 27.83%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Bio-Techne will have a dividend payout ratio of 16.24% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.Read more about Bio-Techne's dividend. News and Social Media2.8 / 5News Sentiment0.44 News SentimentBio-Techne has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Bio-Techne this week, compared to 6 articles on an average week.Search InterestOnly 4 people have searched for TECH on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows1 people have added Bio-Techne to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bio-Techne insiders have not sold or bought any company stock.Percentage Held by Insiders1.30% of the stock of Bio-Techne is held by insiders.Percentage Held by Institutions98.95% of the stock of Bio-Techne is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bio-Techne's insider trading history. Receive TECH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TECH Stock News HeadlinesBio-Techne Corporation Reports Earnings Results for the First Quarter Ended September 30, 2026November 6 at 9:04 PM | marketscreener.comMBio-Techne's $0.08 dividend hinges on Merck KGaA deal timing (NASDAQ: TECH)November 6 at 4:17 AM | americanbankingnews.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets. | Weiss Ratings (Ad)Bio-Techne Corp (TECH) - What Are Researchers Thinking About This Stock?November 5 at 3:31 AM | americanbankingnews.comBio-Techne (TECH), What Is Behind The Fresh Attention Now?November 4, 2026 | finance.yahoo.comBio-Techne Declares Dividend for the Quarter Ended September 30, 2026, Payable on November 23, 2026November 4, 2026 | marketscreener.comMBio-Techne declares $0.08 dividendNovember 4, 2026 | msn.comBIO-TECHNE DECLARES DIVIDENDNovember 3, 2026 | prnewswire.comSee More Headlines TECH Stock Analysis - Frequently Asked Questions How have TECH shares performed this year? Bio-Techne's stock was trading at $58.81 at the beginning of the year. Since then, TECH stock has increased by 23.8% and is now trading at $72.78. How were Bio-Techne's earnings last quarter? Bio-Techne Corp (NASDAQ:TECH) issued its earnings results on Wednesday, November, 4th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.44. The biotechnology company earned $299.71 million during the quarter, compared to analyst estimates of $292.60 million. Bio-Techne had a trailing twelve-month return on equity of 13.23% and a net margin of 14.97%. When did Bio-Techne's stock split? Bio-Techne shares split on the morning of Wednesday, November 30th 2022.The 4-1 split was announced on Tuesday, November 1st 2022. The newly issued shares were distributed to shareholders after the market closes on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. Is Bio-Techne buying back stock? Bio-Techne's board initiated a stock buyback plan on Wednesday, May 7th 2025, which allows the company to repurchase $500 million in outstanding shares, according to EventVestor. This means that the company could purchase up to 6.5% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's board of directors believes its stock is undervalued. Does Bio-Techne have any subsidiaries? The following companies are subsidiaries of Bio-Techne: MoGen Biotechnologies, Exosome Diagnostics, Quad Technologies, Advanced Cell Diagnostics, Space Import-Export Srl, Zephyrus Biosciences, Cliniqa, and others. Who are Bio-Techne's major shareholders? Top institutional investors of Bio-Techne include Russell Investments Group Ltd. (0.10%), New York Life Investment Management LLC (0.08%), Summit Creek Advisors LLC (0.06%) and Nisa Investment Advisors LLC (0.04%). Insiders that own company stock include Roeland Nusse, Kim Kelderman and Amy E Herr. View institutional ownership trends. How do I buy shares of Bio-Techne? Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bio-Techne own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Techne investors own include NVIDIA (NVDA), Amgen (AMGN), Thermo Fisher Scientific (TMO), Broadcom (AVGO), Regeneron Pharmaceuticals (REGN), Abbott Laboratories (ABT) and Alibaba Group (BABA). Company Calendar Record date for 9/4 Dividend8/24/2026Ex-Dividend for 9/4 Dividend8/24/2026Dividend Payable9/04/2026Last Earnings11/04/2026Today11/07/2026Record date for 11/23 Dividend11/13/2026Ex-Dividend for 11/23 Dividend11/13/2026Dividend Payable11/23/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 TECH's financial health is in the Green zone, according to TradeSmith. TECH has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:TECH CIK842023 Webwww.bio-techne.com Phone(612) 379-8854Fax612-656-4400Employees3,000Year Founded1981Price Target and Rating Average Price Target for Bio-Techne$68.92 High Price Target$79.00 Low Price Target$50.00 Potential Upside/Downside-5.3%Consensus RatingHold Rating Score (0-4)2.12 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)$1.15 Trailing P/E Ratio63.29 Forward P/E Ratio36.94 P/E Growth5.28Net Income$181.86 million Net Margins14.97% Pretax Margin19.81% Return on Equity13.23% Return on Assets10.61% Debt Debt-to-Equity Ratio0.09 Current Ratio4.55 Quick Ratio3.35 Sales & Book Value Annual Sales$1.22 billion Price / Sales9.41 Cash Flow$2.35 per share Price / Cash Flow31.00 Book Value$13.47 per share Price / Book5.40Miscellaneous Outstanding Shares157,056,000Free Float155,014,000Market Cap$11.43 billion OptionableOptionable Beta1.29 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:TECH) was last updated on 11/6/2026 by MarketBeat.com Staff. From Our PartnersEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredYour first step can stay on paperIncome Blueprint, created by Matt, helps traders find and evaluate options opportunities. In his walkthrough, ...StocksToTrade | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Techne Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Techne With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
